Preeclampsia today and tomorrow

Česká verze

Authors: Karel Fousek
Authors place of work: Oddělení gynekologie a porodnictví, Městská nemocnice Ostrava, p. o.
Published in the journal: Prakt Gyn 2016; 20(3-4): 122-125
Category: Gynekologie a porodnictví

Summary

Preeclampsia is exclusively pregnancy associated disease originating from altered placentation. This condition causes an imbalance between antiangiogenic and proangiogenic substances in placenta as well as in mother‘s blood stream. In mother’s body endothelial dysfunction, hypertension syndrome and a series of successive states evolve. These can be further diagnosed. On the basis of this knowledge we already have an effective screening of preeclampsia in the I. trimester which allows us to provide efficient prevention. On the other side we still look for a test which would be able as effectively as possible not only diagnose an already on-going preeclampsia, but also state the risk of evolving this condition in the latter phases of pregnancy. A big hope has been recently put into a new bed-side test based on the use of congo red dye, named Congo Red Dot Paper Test.

Key words:
ASA – congo red – pathophysiology – preeclampsia – prevention – screening

Zdroje

1. Leahomschi S, Calda P. Preeklampsie v těhotenství – predikce, prevence a další management. Čes Gynek 2014; 79(5): 356–362.

2. Norwitz E, Buhimschi, IA, Bhandari V et al.. Preeklampsie: screeningový test z moči. Gynekologie po promoci 2007; 7(4): 20–23.

3. Hájek Z, Čech E, Maršál K et al. Porodnictví. 3. ed. Grada Publishing: Praha 2014. ISBN 978–80–247–4529–9.

4. The Fetal Medicine Foundation. Advances in Fetal Medicine Course. London 2016. Dostupné z WWW: <https://fetalmedicine.org>.

5. Valensise H, Lo Presti D, Gagliardi G et al. Persistent Maternal Cardiac Dysfunction after Preeclampsia Identifies Patients at Risk for Recurrent Preeclampsia. Hypertension 2016; 67(4): 738–742.

6. Bujold E, Roberge S, Lacasse Y et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116(2 Pt 1): 402–414. Dostupné z DOI: <http://dx.doi.org/10.1097/AOG.0b013e3181e9322a>.

7. Roberge S, Villa P, Nicolaides K et al. Early Administration of Low-Dose Aspirin for the Prevention of Preterm and Term Preeclampsia: A Systematic Review and Meta-Analysis. Fetal Diagn Ther 2012; 31(3): 141–146. Dostupné z DOI: <http://dx.doi.org/10.1159/000336662>.

8. Caron N, Rivard GE, Michon N et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can 2009; 31(11): 1022–1027.

9. The Fetal Medicine Foundation. Randomized Trials – ASPRE. London 2016. Dostupné z WWW: <https://fetalmedicine.org/research/randomized-trials/aspre-1>.

10. Rood K, Buhimschi CS, Dible T et al. 34: Point-of-care Congo Red Dot (CRD) Test for Antenatal Triage and Rapid Identification of Preeclampsia (PE). Am J Obstet Gynecol 2016; 214(Suppl 1): S24–S25. Dostupné z DOI: <http://dx.doi.org/http://dx.doi.org/10.1016/j.ajog.2015.10.058>.